Date:1/6/2009

(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at http://www.genego.com.

'/>"/>

SOURCE GeneGo, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology
2. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
3. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
4. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
5. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
6. Unilever Extends Their GeneGo MetaCore License
7. VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
8. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
9. GSK Extends GeneGo License and Adds New Products
10. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
11. GeneGo Integrates With Cytoscape